Tandem Diabetes Care Inc. (NASDAQ:TNDM) finished Wednesday with a subtraction of -$4.18 to close at $49.15, a downside of -7.84 percent. An average of 1,412,480 shares of common stock have been traded in the last five days. There was a fall of -$8.88 in the past week, and it reached a new high 18 times over the past 12 months. The last 20 days have seen an average of 1,434,040 shares traded, while the 50-day average volume stands at 1,152,212.
TNDM stock has increased by 4.13% in the last month. The company shares reached their 1-month lowest point of $42.90 on 09/01/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $42.90 and a high of $155.86 in 52 weeks. It has reached a new high 1 time so far this year and lost -67.35% or -$101.37 in price. In spite of this, the price is down -68.47% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
106 days have passed since Tandem Diabetes Care Inc. (TNDM) last reported insider trading activity. BERGER DAVID B, who is EVP & Chief Operating Officer, most recently acquired $10,097 shares at $65.02 per share on Jun 08. In this transaction, the insider spent $656,515. Director, BLICKENSTAFF KIM D, disposed of 10,762 shares at a price of $92.91 on May 17. The insider now owns more than $999,897 worth of shares. Prior to that, Director TWOMEY CHRISTOPHER J went on to Sale 248 shares at $111.73 each on May 05. An amount of $27,709 was transacted.
Tandem Diabetes Care Inc. (TNDM) stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.22, the price-to-book (PB) ratio at 7.00, and the price-to-cash flow ratio at 63.52.
The quick ratio of Tandem Diabetes Care Inc. for the three months ended March 30 was 5.40, and the current ratio was 6.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.63 and a total debt to equity ratio of 0.63 for the quarter ending March 30. Its gross profit as reported stood at $376.21 million compared to revenue of $702.8 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Tandem Diabetes Care Inc.’s return on assets was -1.40%.
For the three-month period that ended March 30, Tandem Diabetes Care Inc. had $520.37 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$15.06 million in the quarter, while revenues of -$14.72 million were grew 126.63%. The analyst consensus anticipated Tandem Diabetes Care Inc.’s latest quarter earnings to come in at -$0.07 per share, but it turned out to be -$0.23, a -228.60% surprise. For the quarter, EBITDA amounted to -$6.99 million. Shareholders own equity worth $64.22 million.
From a technical analysis perspective, let’s take a brief look at Tandem Diabetes Care Inc. (TNDM) price momentum. RSI 9-day as of the close on 21 September was 38.21%, suggesting the stock is Neutral, with historical volatility in this time frame at 64.68%.
As of today, TNDM’s price is $54.61 -15.30% or -$8.88 from its 5-day moving average. TNDM is currently trading +6.89% higher than its 20-day SMA and -50.07% lower than its 100-day SMA. However, the stock’s current price level is -10.31% below the SMA50 and -63.14% below the SMA200.
The stochastic %K and %D were 55.77% and 69.84%, respectively, and the average true range (ATR) was 3.10. With the 14-day stochastic at 36.74% and the average true range at 3.06, the RSI (14) stands at 42.04%. The stock has reached -3.36 on the 9-day MACD Oscillator while the 14-day reading was at 0.03.
Wells Fargo downgraded Tandem Diabetes Care Inc. (NASDAQ: TNDM) to a an Underweight rating in its most recent analyst report. Previously, the stock was rated as an Overweight.